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Background: Equine melanoma has a high incidence in grey horses. Xenogenic DNA vaccination may represent a
promising therapeutic approach against equine melanoma as it successfully induced an immunological response in other
species suffering from melanoma and in healthy horses. In a clinical study, twenty-seven, grey, melanoma-bearing, horses
were assigned to three groups (n = 9) and vaccinated on days 1, 22, and 78 with DNA vectors encoding for equine (eq)
IL-12 and IL-18 alone or in combination with either human glycoprotein (hgp) 100 or human tyrosinase (htyr). Horses
were vaccinated intramuscularly, and one selected melanoma was locally treated by intradermal peritumoral injection.
Prior to each injection and on day 120, the sizes of up to nine melanoma lesions per horse were measured by caliper and
ultrasound. Specific serum antibodies against hgp100 and htyr were measured using cell based flow-cytometric assays.
An Analysis of Variance (ANOVA) for repeated measurements was performed to identify statistically significant influences
on the relative tumor volume. For post-hoc testing a Tukey-Kramer Multiple-Comparison Test was performed to compare
the relative volumes on the different examination days. An ANOVA for repeated measurements was performed to analyse
changes in body temperature over time. A one-way ANOVA was used to evaluate differences in body temperature
between the groups. A p–value < 0.05 was considered significant for all statistical tests applied.
Results: In all groups, the relative tumor volume decreased significantly to 79.1 ± 26.91% by day 120 (p < 0.0001,
Tukey-Kramer Multiple-Comparison Test). Affiliation to treatment group, local treatment and examination modality
had no significant influence on the results (ANOVA for repeated measurements). Neither a cellular nor a humoral
immune response directed against htyr or hgp100 was detected. Horses had an increased body temperature on
the day after vaccination.
Conclusions: This is the first clinical report on a systemic effect against equine melanoma following treatment
with DNA vectors encoding eqIL12 and eqIL18 and formulated with a transfection reagent. Addition of DNA
vectors encoding hgp100 respectively htyr did not potentiate this effect.
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Equine melanoma, a tumor of pigment producing cells,
is the most common skin tumor in aging grey horses
with a prevalence of up to 95% [1].
So far, conventional therapies such as surgical excision
[2], cryosurgery [2], radiotherapy [3], or chemotherapy
with cisplatin [4] or cimetidine [5] have not been curative
in advanced cases. Obviously, there is need for innovative* Correspondence: jessika.cavalleri@tiho-hannover.de
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unless otherwise stated.approaches to treat equine melanoma lesions of later
stages.
Xenogenic DNA vaccination against the melanoma
differentiation antigens glycoprotein (gp) 100 [6-9] and
tyrosinase (tyr) [10-13] have been shown to overcome
auto-tolerance and to elicit an immune response in
mice, dogs, and humans [10-16] and a clinical antitu-
moral effect in mice and dogs [10-12,14,16].
In clinically healthy horses, specific antibodies at rela-
tively low levels and a variable cellular immune response
were elicited upon vaccination with a plasmid encoding
the human tyrosinase (htyr) [17]. There are no reports
about the immunogenicity of human gp100 (hgp100) totral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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effect of DNA-encoded xenogenic tyrosinase and gp100
in grey horses have not been published to date.
Cytokines such as Interleukin (IL) 12 and IL18 have
been applied to increase cellular immunity and reduce
angiogenesis in neoplasms [18-23] and were shown to
have synergistic antitumoral effects [20,24-26].
To date, all immunological melanoma treatment efforts
in horses were of limited effect. A local effect was achieved
with DNA encoding human [27] or either eqIL12 or eqIL18
[28]. Thus, combination of these interleukins and addition
of either hgp100 or htyr, all encoded by DNA vectors,
seemed to be a promising approach.
The aim of the present clinical study was to evaluate
whether or not treatment with eqIL12 in combination
with eqIL18 each encoded by DNA vectors has a local
and systemic anti-tumoral effect on naturally occurring
melanoma in grey horses, and whether or not this effect
is augmented by DNA vaccination against the xenogenic




Twenty-seven horses with one or more melanoma le-
sions and unaffected general condition were included in
the study. Informed consent was obtained from all ani-
mal owners. Horses were not treated with any medica-
tion at least two weeks prior to immunisation.
Pre-trial evaluation included a physical examination,
hematology, and blood biochemistry profile. Age, breed,
gender, degree of greying and number of melanoma lesions
were documented (Table 1). The diagnosis of melanoma
was confirmed by examination of fine needle aspirates by
board certified pathologists in 20 of 27 horses. In the
remaining horses, diagnosis was made clinically with re-
gard to typical localisation and appearance of the lesions,
as the owners did not agree to aspiration biopsy. Patients
were treated in the Clinic for Horses of the University of
Veterinary Medicine Hannover, Foundation, from Novem-
ber 2009 to July 2010 in accordance with the ethical guide-
lines of the law of animal welfare approved by the “Lower
Saxony State Office for Consumer Protection and Food
Safety, LAVES” approval No. 08/1522).
Horses were assigned to three treatment groups by a
stratified biphasic model to achieve equal distribution of
age (<15 years or ≥ 15 years) and number of melanoma
lesions (<7 or ≥ 7 melanoma lesions).
Production of MIDGE-Th1 vectors
Minimalistic immunogenically defined gene expression
(MIDGE) vectors with a small peptide (“Th1”) attached
were produced by MOLOGEN AG (Berlin, Germany) as
previously described [29] from plasmids coding for hgp100 (pcDNA3gp100, courtesy of Dr. Robbins und Dr.
Rosenberg, National Cancer Institute), htyr (pMCV1.4htyr,
MOLOGEN AG), eqIL12 and eqIL18 (pUSErIRESeqIL12
and 18, courtesy of L. Nicholson, University of Glasgow, via
Intervet International, Boxmeer, The Netherlands). Oligo-
nucleotides coding for the IL-1beta receptor antagonist
protein (ILRAP) (Microsynth, Balgach, Switzerland) were li-
gated to the IL18 gene (see Additional file 1).
Preparation of MIDGE-Th1/SAINT-18 complexes
MIDGE-Th1/SAINT-18 (1-methyl-4-(cis-9-dioleyl) methyl-
pyridinium-chloride, Synvolux Therapeutics, Groningen,
The Netherlands) complexes were prepared as described by
Endmann et al. [30]. MIDGE-Th1/SAINT-18 complexes
were formed at a ratio of 1 mg DNA dissolved in PBS to
0.75 μmol SAINT-18. The PBS concentration in the final
mixture was 1× PBS.
Treatment
Three groups of 9 grey horses each were treated on
days 1, 22 and 78 with MIDGE-Th1 vectors coding for
eqIL12 and ILRAP-eqIL18 alone or in combination
with hgp100MIDGE-Th1 or htyrMIDGE-Th1 (Table 2).
Throughout the study period the test items were blinded
by a color code and unblinded upon completion of data
analysis only.
For each treatment, 0.5 ml (half of the vaccine dose)
were injected intradermally (i.d.) peritumorally around
one pre-selected, well-measureable and easily-accessible
melanoma (“locally treated melanoma”). Injection was
performed using a 25 G cannula and a 1 ml syringe. An-
other 0.5 ml (the second half of the dose) were adminis-
tered intramuscularly (i.m.) into the semimembranosus
muscle using a 22 G cannula and a 1 ml syringe. The
identical injection sites were used for the first, second
and third immunisation.
Clinical evaluation for determination of response to
treatment
In each horse the locally treated melanoma and up to eight
additional melanoma lesions (“non-locally treated melan-
oma lesions”) were monitored prior to each injection and
on day 120 using calipers and ultrasound (LogiQ P5,
General Electrics, Connecticut, USA). The ultrasonographic
measurements were performed independently by two ex-
aminers. All measurements were performed in triplicates.
The length (mm, longest diameter), width (mm, perpen-
dicular to length), and depth (mm, only by ultrasound)
were documented and the tumor volume (cm3) calculated
(volume = length × width2 × 0.5 for caliper measurements
and volume = length × width x depth × 0.5 for ultrasono-
graphic measurements).
The relative volumes were calculated in reference to
the volume on day one (pre-dosing), which was defined





Breed Sex Color Number of
Melanoma
FNA Localisation
eqIL12, eqIL18 1 22 Warmblood m flea
bitten
>7 no vt, mu, o
2 18 Warmblood g flea
bitten
1 yes vt
7 20 Icelandic-Horse m white >7 yes pa, vt, ge
9 12 Berber m white >7 yes pa, vt, ge, p
12 11 Carmargue m dappled >7 no vt, pa, ge, p
13 11 Shetland g dappled 3 no pa, ge, vt
17 17 Andalusian m white >7 yes pa, vt, ge, mu,
o
23 14 Arabian g flea-
bitten
1 yes p
24 16 Warmblood m flea-
bitten
>7 yes pa, vt, ge
eqIL12, eqIL18, hgp100 3 18 unclassified g flea
bitten
1 yes pa
5 12 Andalusian m dappled >7 yes pa, vt, mu, p, o
6 18 Andalusian s white >7 no e, vt, ge
8 15 Berber s white >7 yes pa, vt
15 14 Andalusian s white >7 no pa, vt
18 16 Warmblood m white >7 yes pa, vt, ge
19 15 Arabian g flea-
bitten
>7 yes p
22 14 Warmblood m flea-
bitten
2 no pa, vt
27 22 Icelandic-Horse m flea-
bitten
>7 yes pa, vt, ge
eqIL12, eqIL18, htyr 4 19 Arabian s flea
bitten
>7 yes pa, vt
10 15 Arabian s white >7 yes pa, vt, mu
11 20 Carmargue s white 4 no vt
14 15 Shetland m white >7 no vt
16 13 Warmblood m flea-
bitten
2 yes pa, vt
20 22 Trakehner g white >7 yes pa, vt
21 19 Arabian g white 1 yes vt
25 13 Arabian m white >7 yes pa, vt, ge, mu,
o
26 11 Irish horse
(Hunter)
g white 1 yes vt
Legend:
m: mare vt: ventral tail e: eyelid
g: gelding p: parotid region mu: muscle
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Table 2 Treatment substances administered to horses of
the three treatment groups on days 1, 22 and 78







MIDGE-Th1 eqIL12 200 μg 200 μg 200 μg
MIDGE-Th1 eqILRAPIL18 200 μg 200 μg 200 μg
MIDGE-Th1 hgp100 - 500 μg -
MIDGE-Th1 htyr - - 500 μg
SAINT 18 0.35 μmol 0.675 μmol 0.675 μmol
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lesions of each horse, a mean value per time point was
calculated to statistically evaluate the effect on these tu-
mors, i.e. the systemic effect of the treatment. Further-
more, the change of tumor volume was calculated by
subtraction of the relative volume on day 1 (100%) from
the relative volume on day 120 (%), with a negative value
implying tumor reduction and a positive value standing
for tumor growth.
These measurements and calculations were used in
previous studies investigating the effect of gene therapies
against equine melanoma [28] and were found to be ap-
propriate for this mostly slow growing tumor and for
comparability with aforementioned studies.Clinical evaluation of safety of treatment
Horses were hospitalized for 3 days after each injection.
Safety and tolerability of the treatment were evaluated
by clinical examination, hematologic and blood bio-
chemistry profile: a general clinical examination was per-
formed before injection, on each day of hospitalisation
and on day 120. A hematologic examination was realized
before injection, on the 3rd day after injection and on
day 120, a biochemistry profile was accomplished before
each injection and on day 120. The injection sites were
monitored for signs of local inflammation and depig-
mentation. Other pigmented skin areas (eyelids, nostrils)
were observed for signs of depigmentation.Measurement of the immune response induced by
vaccination
To measure specific serum antibodies against hgp100
and htyr a cell based, flow cytometric antibody assay was
performed. Therefore, sera from the patients were ob-
tained before each injection and on day 120. The sera
were incubated with hgp100 and htyr plasmid trans-
fected HEK 293 cells. Evaluation was performed by flow
cytometry after staining bounded antibodies with a sec-
ondary antibody (see Appendix A, Additional file 1).
At any time post-vaccination a humoral response was
considered positive when fluorescence increased ≥ 3standard deviations over the mean value at baseline and
had an absolute value > 0.1%.
The establishment of an assay to detect a potential T-
cell response induced by the vaccine was not followed
up after transfection rates of primary autologous dermal
cells, derived from skin of patients were inconsistent and
low. Thus expression of antigens was insufficient to in-
duce T cell activation after co-culture of transfected cells
and peripheral blood mononuclear cells (data not
shown).
In vitro expression of transgenes eqIL12, eqIL18, htyr and
hgp100 on mRNA level
Chinese hamster ovary (CHO)-K1 cells (ATCC CCL-61)
were cultured in Ham`s F12 (10% FCS, 1% Penicillin/
Streptomycin) medium at 37°C in 5% CO2. Prior to
transfection the culture medium was removed, cells were
washed once with PBS, then detached with trypsin/
EDTA and 0.12E + 06 cells per well suspended in 500 μL
transfection medium (Ham`s F12 cell culture medium
w/o additives). 100 μL of each DNA/SAINT-18 complex
were prepared as follows: MIDGE-Th1 vectors were
mixed with previously vortexed SAINT-18 (0.75 mM) at
a ratio of 5 μl SAINT-18 per μg DNA and filled up to
100 μL with HBS. Complexes were allowed to form for
5 min. Cells were incubated with complexes containing
a) MIDGE-Th1 vectors encoding eqIL12 and eqIL18
(0.5 μg per vector), b) MIDGE-Th1 vectors encoding
eqIL12 (0.5 μg), eqIL18 (0.5 μg) and htyr (1.25 μg), c)
MIDGE-Th1 vectors encoding eqIL12 (0.5 μg), eqIL18
(0.5 μg) and hgp100 (1.25 μg) and d) MIDGE-Th1 vec-
tors encoding eGFP (1.25 μg) as positive control for the
transfection method and CHO-K1 expression efficiency
(measured by FACS). Salmon sperm DNA (Invitrogen)
served as negative control item. The DNA SAINT-18
complexes were added to the cells, followed by a brief
centrifugation step. After 2.5 hours of incubation, 1 mL
of complete Ham`s F12 was added and cells incubated
for 24 hours at 37°C in 5% CO2. Cells were harvested
and detached as described above, centrifuged and pellets
stored on ice until RNA was extracted using the
NucleoSpin RNA II Kit (Macherey & Nagel) as described
in provider`s instructions.
mRNA specific Reverse Transcription quantitative PCR
(RT-qPCR) was performed with 100 ng mRNA per reac-
tion using the TaqMan® RNA-to-CT 1-Step Kit (Applied
Biosystems) according to manufacturer`s instructions.
Primers and probes (TIBMOLBIOL, Berlin) had specific
sequences to generate and detect cDNA of eqIL12-p35
(fw 5`-AAATTGCTAACGCAGTCAGT-3`, rv 5`-GCT
AGCTCCGGAGTT-3`, probe FAM-CGACTGATCACA
GGGGTACC-BBQ), eqIL12-p40 (fw 5`-AAATTGCTAAC
GCAGTCAGT-3`, rv 5`-GACCAACCACTGGTGAC-3`,
probe FAM-CGACTGATCACAGGGGTACC-BBQ), eqIL18
Mählmann et al. BMC Veterinary Research  (2015) 11:107 Page 5 of 11(fw 5`-AAATTGCTAACGCAGTCAGT-3`, rv 5`-GAGGC
CTCTGCAGATT-3`, probe FAM-CGACTGATCACAGGG
GTACC_BBQ), hgp100 (fw 5`-AAATTGCTAACGCAGTC
AGT-3`, rv 5`-AGCCAAATGAAGAAGGCATC −3`, probe
FAM-CGACTGATCACAGGGGTACC-BBQ) and htyr (fw
5`-AAATTGCTAACGCAGTCAGT-3`, rv 5`-CCACAGCA
GGCAGTAC −3`, probe FAM-CGACTGATCACAGGGGT
ACC-BBQ). Samples were measured in technical triplicates.
Statistical analysis
An Analysis of Variance (ANOVA) for repeated measure-
ments was performed to identify statistically significant
influences on the relative tumor volume. Parameters in-
cluded in the model were the individual horse, examin-
ation day (1, 22, 78, 120), treatment group (eqIL12/18,
hgp100, htyr), locally treated versus non-locally treated
melanoma lesions and examination method (caliper and
ultrasound with differentiation between the two exam-
iners). After starting with the full model, non-significant
variables and correlations were eliminated stepwise.
For post-hoc testing a Tukey-Kramer Multiple-Comparison
Test was performed to compare the relative volumes
on the different examination days.
An ANOVA for repeated measurements was performed
to analyse changes in body temperature over time. A one-
way ANOVA was used to evaluate differences in body
temperature between the groups.
A p–value < 0.05 was considered significant for all stat-
istical tests applied.
Statistical analyses were performed using the statistical
software JMP 8.0 (SAS Institute Inc., Cary, NC, USA)
and NCSS (NCSS, Kaysville, Utha, USA).
Results
Safety of treatment
Based on the clinical examinations of the horses the
vaccine was safe and well tolerated. The only consistent
abnormal finding was a significant increase in body
temperature on the day after injection (p < 0.00001,
Figure 1). No difference in body temperature between
the groups (p = 0.98) was observed. Hematology and
blood biochemistry profile revealed no abnormalities at
any time point. At the intradermal injection sites (3x27
injections = 81 injections in total), horses showed mild
subcutaneous swelling (81/81 injections), reddening (10/
81), exudation (7/81) and mild ulceration (2/81). These
signs of acute inflammation occurred within the first three
days after injection and resolved until the next treatment
except in horse 11 were they persisted for 21 days after
the first injection. Twentysix of 27 horses developed local
dermal depigmentation restricted to the intradermal injec-
tion sites, only. The depigmentation was first observed
after 22 days in 23 horses and after 81 days in 3 more
horses. There were no signs of depigmentation observedin the monitored pigmented regions or melanoma lesions.
No differences of local reactions were noted between
treatment groups. No local reactions were observed at the
sites of intramuscular injections.
Caliper and ultrasonographic measurements of tumor
size
In total 136 melanoma lesions (groups IL12/18: n = 42,
hgp100: n = 50, htyr: n = 44) were measured. After step-
wise elimination of insignificant variables and correla-
tions the only variable influencing the relative volume
was the examination day (p = 0.00001) and an individual
effect of the horses. Post-hoc testing showed a signifi-
cant decrease of the relative melanoma-volume over
time. Mean relative volume of all measured melanoma
decreased significantly to 71.5 ± 29.73% - equalling to
28.5% of tumor volume reduction - as measured by cali-
per and 87.0 ± 24.42% (13% tumor volume reduction),
82.1 ± 28.02% (17.9% tumor volume reduction) as mea-
sured by ultrasonography (ultrasound examiner 1, ultra-
sound examiner 2) (Figure 2, Table 3). The relative
tumor volume ranged from 0 to 205% (caliper) and 0 to
194, 196% (ultrasound examiner 1, ultrasound examiner
2) at day 120.
Measurement of the humoral response induced by
vaccination
No specific antibodies against htyr or hgp100 were de-
tected in equine sera collected on days 1, 22, 78 and 120
(see Additional file 2: Figure S1).Proof of function of DNA vectors: In vitro expression
The expression of all encoded genes was proven on
mRNA level after transfection of cells in vitro. MIDGE-
Th1 vectors were used in mixtures at weight ratios equal
to those administered to the patients and complexed with
SAINT-18. The amount of cDNA generated from mRNA
was analysed in a RT-qPCR assay using a plasmid stand-
ard, allowing for detection and estimation of the mRNA
expression levels produced from individual transgenes.
eqIL12, eqIL18, htyr and hgp100 were shown to be
expressed from all respective mixtures of MIDGE-Th1
vectors (Table 4).
Discussion
In the present clinical study, three treatments with mix-
tures of MIDGE-Th1 eqIL12 and ILRAP-eqIL18 alone
or in combination with MIDGE-Th1 hgp100 or MIDGE-
Th1 htyr, all complexed with the cationic transfection
agent SAINT-18, resulted in a moderate reduction of the
relative volume of examined melanoma lesions (28.5%).
The lack of differences in treatment effects between the
three groups suggests that MIDGE-Th1 hgp100 or
Figure 1 Daily rectal temperatures (in °C) measured in 27 horses before each injection (1) and on three consecutive days. There was a significant
transient increase in the temperature on the first day after injection (Tukey-Kramer Multiple Comparison Test). The center horizontal line of
the box plot marks the median of the sample. The edges of the box mark the first and third quartiles. The dotted lines define the 75th
percentile plus 1.5 times the interquartile range (IQR) and the 25th percentile minus 1.5 times IQR. The singular dots represent the outside
values. *** Significant difference (p ≤ 0.0001).
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other components of the treatment.
In former studies on equine melanoma the placebo
group showed progression or no change in size during
the study period of 64 days [28,31]. A placebo group was
not included in this study because a positive anti-
tumoral effect of treatment with interleukin-12 and −18
DNA had been demonstrated in these earlier studies.
Ethical considerations regarding withholding any poten-
tially effective treatment from client-owned horses pre-
cluded inclusion of an untreated cohort. However, it is
reasonable to attribute the tumor size reduction ob-
served in this study to the treatment, as no spontaneous
regression of equine melanoma lesions has been re-
ported up to date. Importantly, the size reduction was
not only seen in locally treated but also in non-locally
treated melanoma lesions indicating a systemic effect of
the treatment. Comparing the development of volume of
peritumorally treated and distant melanoma lesions,
there was no statistically significant difference observed.
The systemic effect might be based on a primarily un-
specific immune response that, in the presence of mel-
anoma antigens, converted into an anti-melanoma
specific immune response. However, this is a hypothesis
only since such aspecific immune response has not been
detected in our assays.The present study was the first to use a combination
of DNA vectors encoding eqIL12 and eqIL18 for the
therapy of equine melanoma. Previously either eqIL18 or
eqIL12 DNA injected intratumorally induced some size
reduction in equine melanoma lesions [28] but systemic
effects were not evaluated. Experimental studies in mice
[24,25] have proven synergistic effects of IL12 and IL18,
suppressing collateral [26] or distant tumor growth [20].
In the present study the cationic-amphiphilic transfec-
tion agent SAINT-18 was used to enhance expression
in vivo. SAINT-18 has been reported to strengthen the
immune response against antigens encoded by MIDGE-
Th1 vectors [32,30]. While the complexed DNA was
very well tolerated in mice and rats [30], in the horses of
the study presented here it caused local inflammation at
the site of intradermal injection. This could be either ex-
plained by an inflammatory reaction triggered by the
two expressed cytokines eqIL12 and eqIL18 upon trans-
fection of dermal cells, or respectively and by a higher
sensitivity of horses against DNA complexed with SAINT-
18. In mice, expressed cytokines were found to mediate
antitumoral effects by reduction of angiogenesis [20] as
well as improved cellular immunity represented by in-
creased IFNγ production and enhanced cytotoxic T- and
Natural Killer cell activities [25]. In addition to the local
reaction, horses developed fever on the day post injection,
Figure 2 (See legend on next page.)
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Figure 2 a): Relative volumes (%) of locally and non-locally treated melanoma lesions calculated by caliper and ultrasound measurements (ultrasound
examiner 1 and 2) on days 1, 22, 78 and 120. Relative volume of melanoma lesions decreased significantly from day 1 to 120 (Tukey-Kramer Multiple
Comparisons Test). There were no statistically significant differences detected between the treatment groups, locally or non-locally treated melanoma
lesions and measurement modality/ultrasound examiner. Dots, squares and triangles represent the median and the vertical lines the standard deviations.
*** Significant difference (p≤ 0.0001). b): Relative volumes (%) of non-locally treated melanoma lesions calculated by caliper measurements on days 0, 22,
78 and 120. Relative volume of all non-locally treated melanoma lesions decreased significantly on day 120. There were no statistically significant
differences detected between the treatment groups. *** Significant difference (p≤ 0.0001). c): Relative volumes (%) of locally treated melanoma lesions
calculated by caliper measurements on days 0, 22, 78 and 120. Relative volume of all locally treated melanoma lesions decreased significantly on day 120.
There were no statistically significant differences detected between the treatment groups. . *** Significant difference (p≤ 0.0001). d): Relative volumes (%)
of non-locally treated melanoma lesions calculated by ultrasonographic measurements on days 0, 22, 78 and 120. Relative volume of all non-locally
treated melanoma lesions decreased significantly on day 120. There were no statistically significant differences detected between the treatment groups. .
*** Significant difference (p≤ 0.0001). e): Relative volumes (%) of locally treated melanoma lesions calculated by ultrasonographic measurements on
days 0, 22, 78 and 120. Relative volume of all locally treated melanoma lesions decreased significantly on day 120. There were no statistically significant
differences detected between the treatment groups. . *** Significant difference (p≤ 0.0001).
Table 3 Relative volume of melanoma lesions measured by calipers in individual horses on Day 120, and number of
new lesions by Day 120
Treatment
(encoded genes)
Horse ID % of reduction of the tumor volumes at day







eqIL12, eqIL18 1 −16 −35,- 31,-30,-17, 2, 7, 10, 23 0
2 −38 −40 0
7 −33 −69, −7, −4 0
9 2 −42, −24, −16 0
12 −35 −78, −49, −46, −42, −26 0
13 0 −39, −32 0
17 −43 −40, −11, −8 0
23 −47 - 0
24 −26 −40, −21, −19, −12, −8, −4, −3, −3 0
eqIL12, eqIL18, hgp100 3 48 - 0
5 −46 −56, −50, −36, 6 0
6 −31 −75, −61, −40, −33, −6 0
8 −59 −56, −49, −31, −31, −23, −15, 9, 22 0
15 −46 −58, −43, −37, −23, −27, −21, 0, 0 0
18 −16 −53, −41, −35, −25, −24, −23, −21, −20 0
19 −43 −36 0
22 −8 −47 0
27 −45 −73, −45, −23, −15, −12, 0 0
eqIL12, eqIL18, htyr 4 −59 −79, −50, −32, −27, −24, −14, −12, 105 0
10 −79 −65, −42, −32, −32, −22, −7, −5, 33 0
11 −25 −58, −56, −46 0
14 −71 −46, −32, −31 0
16 −1 −33 0
20 −20 −55, −46, −17, −15, −9, −5, −3, 12 0
21 −38 - 0
25 −18 −38, −30, −5, −15 0
26 7 - 0
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Table 4 Results of RT-qPCR to evaluate in vitro expression of transgenes from MIDGE-Th1 vectors encoding eqIL12,
eqIL18, htyr and hgp100
MIDGE-Th1 Estimated mRNA/cDNA copy numbers per transgene (Ct values)
Vectors [μg] eqIL12-p35 eqIL12-p40 eqIL18 htyr hgp100
eqIL12, eqIL18 [0.5 + 0.5] 1.14 + E03(27) 1.52 + E04(23) 3.16 + E03(25) < LOD < LOD
eqIL12, eqIL18, htyr [0.5 + 0.5 + 1.25] 1.01 + E03(28) 2.10 + E04(23) 5.23 + E03(25) 3.01 + E04(22) < LOD
eqIL12, eqIL18, gp100 [0.5 + 0.5 + 1.25] 9.10 + E02(28) 9.79 + E03(24) 1.98 + E03(26) < LOD 1.30 + E04(23)
LOD (limit of detection): = < 25 copies/reaction.
Mählmann et al. BMC Veterinary Research  (2015) 11:107 Page 9 of 11a systemic reaction to the treatment. Dow et al. [33]
showed that i.v. injections of plasmid DNA complexed
with lipid-protamine with non-coding DNA, resulted in
local inflammation of the lung and other organs of mice.
Thus, it is possible that in the present study fever and the
local inflammation were in part induced by the complexes
of DNA and transfection agent. In mice injection of
SAINT-18 formulated DNA was tolerated well. Neither
local nor systemic signs of intolerance were observed [30].
The use of SAINT-18 in pigs proved to enhance their
humoral immune response to DNA vaccination. The study
did not mention adverse side effects of the transfection re-
agent [32]. However both, the fever as well as the signs of
acute inflammation were transient and are therefore con-
sidered not to be a serious drawback regarding the safety
of the vaccination. As Dow et al. [33,34] showed also that
lipoplexes with DNA encoding IL12 induced a more
effective antitumor response than lipoplexes with non-
coding plasmid DNA in mice the effect of the DNA-
SAINT-18-complex might have potentially enhanced the
antitumoral effect of the Interleukins.
The tumor size reduction in the present study was
moderate and – according to the Response Evaluation
Criteria In Solid Tumors (RECIST) [35] or immune-
related Response Criteria (irRC) [36] used in human
medicine - would not be considered as tumor regression
but as stable disease. However, Wolchok et al. consider
stable disease as a positive therapeutic outcome in can-
cer immunotherapy [36].
Dosages of 100, 500 and 1500 μg plasmid DNA for
hgp100 in humans [8] and for htyr in dogs [12] suc-
cessfully induced detectable immune responses. In the
studies of Lembcke et al. [17] and Phillips et al. [37] a
dosage of only 100 μg plasmid induced a measurable,
though variable and relatively weak, immune response
in nontumor-bearing healthy horses. Thus the doses
used in our study, i.e. 500 μg per antigen encoding
MIDGE-Th1 vector per application should have been
appropriate to induce a detectable immune response.
Moreover, MIDGE-vectors are devoid of plasmid back-
bone DNA and therefore have a smaller molecule size,
so their effective transgene dose per microgram DNA is
much higher than that of conventional plasmids [30].Tyrosinase and gp100 were found to be (over-)expressed
in equine melanoma lesions [32,38,39]. Homology be-
tween equine and human proteins is comparable to the
proteins of mice compared to human for gp100 [75.5%
[16]] and canine tyrosinase as well as the mouse and hu-
man equivalent [84.4% and 87.5% [12]]. Since xenogenic
DNA vaccination encoding these proteins in mice and dogs
induced an antitumoral immune response [10-12,14,16] it
can be assumed that the proteins chosen and the differ-
ence in the amino acid sequence are adequate.
The vaccination interval used in the recent study is
comparable to immunisation strategies for infectious
diseases and also to a therapeutic vaccination protocol
against melanoma in humans [40]. However, vaccination
against tumors generally elicits a weaker immunity than
vaccination against infectious diseases [41]. In other
studies, in which an immunological response was suc-
cessfully induced, more frequent application schemes for
therapeutical antitumor vaccines [8,12,13] or cytokine
gene therapy were used [42]. Lembcke et al. [17] vacci-
nated healthy horses four times with human tyrosinase
DNA every two weeks, resulting in the successful induc-
tion of specific antibodies and IFNγ producing cells.
They stated that the altered immunologic status of
tumor-bearing patients (tumor tolerance) might make it
more challenging to induce a specific immune response
to tumor antigens than in healthy animals [17].
No specific humoral response could be observed in
the present study.. In future studies additional tests to
evaluate the cellular immune response [17] might give
additional information about immunological mecha-
nisms. However, in contrast to studies by Lembcke
et al. [17] and Phillips et al. [37], we treated melanoma-
bearing horses which might have developed an immune
tolerance to gp100 and tyrosinase previously. To over-
come this specific immune tolerance, higher DNA doses
encoding xenogenic antigens and/or a more condensed
immunisation schedule than in the present study might be
necessary to induce a detectable immune response.
Conclusions
In the present study, treatment of horses with MIDGE-Th1
vectors encoding eqIL12 and ILRAP-eqIL18 alone or in
Mählmann et al. BMC Veterinary Research  (2015) 11:107 Page 10 of 11combination with MIDGE-Th1 vectors encoding hgp100 or
human htyr, all complexed with the transfection agent
SAINT-18 resulted in a measurable systemic antitumoral
effect on equine melanoma lesions. To our knowledge this
is the first report on a systemic antitumoral effect against
equine melanoma upon treatment with DNA vectors.
Because no specific immune response was detected, it
remains to be elucidated whether this systemic antitu-
moral effect was caused by interleukins expressed from
the DNA vectors, or an unspecific immune reaction to
the combination of DNA and transfection reagent.
In future studies, a stronger anti-tumoral effect as well
as a detectable specific immune response may be in-
duced by an increased vaccine dose and/or an improved
dosing schedule. Additionally, more sensitive immune
assays should be applied to characterize the immune re-
sponse in detail.Additional files
Additional file 1: Contains supplementary text file 1.
Additional file 2: Figure S1. No specific antibodies were detected in
serum samples from vaccinated horses on days 1, 22, 78 and 120.
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